Increase Tresiba dose and strongly consider adding a GLP-1 receptor agonist
With fasting glucose >200 mg/dL and A1c 8.4% on 50 units of Tresiba, you should immediately titrate the basal insulin upward by 2 units every 3 days until fasting glucose reaches target (typically 80-130 mg/dL), and simultaneously add a GLP-1 RA before considering prandial insulin. 1
Immediate Actions
1. Discontinue Glipizide
Stop the glipizide now that the patient is on insulin. Sulfonylureas should be discontinued once insulin is initiated to reduce hypoglycemia risk 2. This combination provides minimal additional benefit and increases hypoglycemia risk.
2. Titrate Tresiba Aggressively
The current 50-unit dose is clearly insufficient given the fasting glucose >200 mg/dL. According to the 2025 ADA Standards 1:
- Increase by 2 units every 3 days until fasting plasma glucose reaches the individualized target (typically 80-130 mg/dL)
- For hypoglycemia: determine cause; if no clear reason, lower dose by 10-20%
- Continue titration until adequate glycemic control is achieved
The FDA label for Tresiba 3 confirms this approach, recommending 3-4 days between dose increases. Many patients require 0.5-1.0 units/kg/day 4, which for an average-weight patient could mean 80-100+ units daily.
3. Add a GLP-1 Receptor Agonist NOW
This is the critical step most clinicians miss. Before adding prandial insulin, add a GLP-1 RA 1, 2:
- GLP-1 RAs should be considered in all patients before intensifying to prandial insulin
- They provide additional A1c reduction (typically 1-1.5%) without hypoglycemia risk
- They offer cardiovascular and renal protection
- They prevent weight gain associated with insulin intensification
- Consider agents with proven cardiovascular benefit if the patient has CVD
The 2025 ADA guidelines explicitly state: "If A1C is above goal and the individual is not already on a GLP-1 RA or dual GIP and GLP-1 RA, consider these classes in combination with insulin" 1.
Why This Approach?
Avoid Overbasalization
The patient is likely experiencing overbasalization—continuing basal insulin alone without achieving target. Clinical signals include:
- Elevated bedtime-to-morning differential
- Fasting glucose >200 mg/dL despite 50 units of basal insulin
- A1c 8.4% indicating overall poor control
Simply increasing Tresiba further without adding a GLP-1 RA will likely lead to:
- Excessive weight gain
- Increased hypoglycemia risk
- Failure to address postprandial hyperglycemia
The Evidence-Based Sequence
The 2022 ADA/EASD consensus 2 and 2025 ADA Standards 1 are clear:
- Optimize basal insulin dose (titrate to fasting glucose target)
- Add GLP-1 RA before prandial insulin
- Only add prandial insulin if A1c remains above goal after steps 1-2
If GLP-1 RA is Not an Option
If cost, access, or patient preference precludes GLP-1 RA use, and A1c remains >8% after optimizing basal insulin:
Add Prandial Insulin
- Start with 4 units of rapid-acting insulin before the largest meal 1
- Alternatively, use 10% of the basal insulin dose (5 units in this case)
- Titrate by 1-2 units or 10-15% every 3 days based on postprandial glucose
- Monitor for hypoglycemia and adjust accordingly
Monitoring and Follow-up
- Reassess in 3-6 months to avoid therapeutic inertia 1
- Increase frequency of blood glucose monitoring during titration 3
- Set clear fasting plasma glucose targets with the patient
- Consider continuous glucose monitoring if available to assess time in range and nocturnal hypoglycemia risk 5
Common Pitfalls to Avoid
- Therapeutic inertia: Don't wait months to adjust—titrate every 3 days
- Continuing glipizide: Increases hypoglycemia without meaningful benefit
- Skipping GLP-1 RA: Going straight to prandial insulin misses an opportunity for better outcomes with less burden
- Undertitrating basal insulin: Many patients need >0.5 units/kg/day; don't be afraid to go higher if fasting glucose remains elevated
- Not addressing lifestyle: Reinforce behavioral interventions and refer to diabetes self-management education 1